Sartorius Stedim Biotech SA 2023 IR
The report outlines Sartorius Stedim Biotech's performance in 2023, a year marked by demand normalization following pandemic-related growth. Sales revenue declined by 18.7% in constant currencies to 2,775.5 million euros, while the company adjusted its headcount to 10,662 employees. Strategically, the company expanded its cell and gene therapy portfolio through the key acquisition of Polyplus. On sustainability, the company committed to net-climate neutrality by 2045 and set a target to achieve at least 75% of sales from circular-designed products by 2030.
Company: Sartorius Stedim Biotech SA
Sector: Health Care
Country: France
Year: 2023
Type: IR
Pages: 247
Sartorius Stedim Biotech SA
Universal Registration Document
The report outlines Sartorius Stedim Biotech's performance in 2023, a year marked by demand normalization following pandemic-related growth. Sales revenue declined by 18.7% in constant currencies to 2,775.5 million euros, while the company adjusted its headcount to 10,662 employees. Strategically, the company expanded its cell and gene therapy portfolio through the key acquisition of Polyplus. On sustainability, the company committed to net-climate neutrality by 2045 and set a target to achieve at least 75% of sales from circular-designed products by 2030.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Feb 15, 2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Net Zero Target
Employees